Novel protein kinase inhibitors related to tau pathology modulate tau protein-self interaction using a luciferase complementation assay

Article abstract of DOI:10.3390/molecules23092335

The current number of drugs available for the treatment of Alzheimer's disease (AD) is strongly limited and their benefit for therapy is given only in the early state of the disease. An effective therapy should affect those processes which mainly contribu